Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acyclovir Velpharm
- Development stage
- Unknown
- Lead developer
- Velpharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Acyclovir Velpharm (Ацикловир Велфарм) is an approved generic antiviral drug developed and marketed by the Russian pharmaceutical company Velpharm. Its active ingredient is acyclovir, a synthetic purine nucleoside analogue that selectively inhibits the replication of herpesviruses, including herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), and cytomegalovirus (CMV). Acyclovir is selectively phosphorylated by viral thymidine kinase into its active triphosphate form, which then acts as both an inhibitor and a substrate for viral DNA polymerase, leading to DNA chain termination. Formulated as oral tablets (200 mg and 400 mg), Acyclovir Velpharm is indicated for the treatment and prevention of HSV infections (including genital herpes), chickenpox, and herpes zoster (shingles).
- Brand names
- Acyclovir VelpharmАцикловир Велфарм
02
Targets
DNAHerpesvirus DNA polymerase
Beyond the preview
Go deeper on Acyclovir Velpharm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acyclovir Velpharm.